Alnylam Pharmaceuticals Inc

NASDAQ:ALNY   3:59:53 PM EDT
231.22
-2.63 (-1.12%)
Products, Regulatory, Earnings Announcements

Alnylam Reports Positive Topline Results From APOLLO-B Phase 3 Study Of Patisiran In Patients With ATTR Amyloidosis With Cardiomyopathy

Published: 08/03/2022 11:25 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Alnylam Reports Positive Topline Results From Apollo-b Phase 3 Study of Patisiran in Patients With Attr Amyloidosis With Cardiomyopathy.
Alnylam Reports Positive Topline Results From Apollo-b Phase 3 Study of Patisiran in Patients With Attr Amyloidosis With Cardiomyopathy.
Alnylam Pharmaceuticals Inc - Plans to File a Supplemental New Drug Application in U.S. in Late 2022.
Alnylam Pharmaceuticals Inc - Patisiran Also Met First Secondary Endpoint.
Alnylam Pharma - Patisiran Met Primary Endpoint With a Statistically Significant Improvement in 6-minute Walk Test Compared to Placebo at 12 Months.
Revenue is expected to be $292.21 Million
Adjusted EPS is expected to be -$1.75

Next Quarter Revenue Guidance is expected to be $334.59 Million
Next Quarter EPS Guidance is expected to be -$1.64

More details on our Analysts Page.